平安好醫生(01833.HK)與輝瑞、中華社會救助基金會達成血友病救助戰略合作
平安好醫生(01833.HK)表示,近日於進博會上與輝瑞(PFE.US)及中華社會救助基金會正式簽署關於支持綜合關愛血友病患者「精準救助,回歸社會」戰略合作備忘錄,未來各方將充分發揮各自優勢,進一步踐行綜合關愛理念,支持血友病患者回歸社會。
根據協議,三方將發揮各自優勢,為患者解決診斷、治療、康復、療效檢測、支付方案五大需求,預期來自政府、企業、公益組織、志願者等社會各界力量的共同參與,將為血友病患者創造回歸正常生活的良好環境,支持血友病患者回歸社會,以及幫助患者就近接受同質化規範化的診治。(gc/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.